Abstract
Objective The rapid and early detection of infections and antibiotic resistance markers is a critical challenge in healthcare. Currently, most commercial diagnostic tools for analyzing antimicrobial resistance patterns of pathogens require elaborate culture-based testing. Our study aims to develop a rapid, accurate molecular detection system that can be used directly from culture, thereby introducing molecular testing in conjunction with culture tests to reduce turnaround time (TAT) and guide therapy.
Methods PathCrisp assay, a combination of Loop-mediated Isothermal Amplification (LAMP) and CRISPR-based detection, maintained at a single temperature, was designed and tested on clinical isolates. The specificity and sensitivity of the assay was analyzed, post which the assay was compared with the Polymerase Chain Reaction (PCR) method to detect the New Delhi metallo-beta-lactamase (NDM) gene in carbapenem-resistant Enterobacteriaceae (CRE) clinical samples.
Results Our PathCrisp assay demonstrated the ability to detect as few as 700 copies of the NDM gene from clinical isolates. Our assay demonstrated 100% concordance with the PCR-Sanger sequencing method, more commonly used. Additionally, the lack of the need for a kit-based DNA purification step, rather a crude extraction via heating, enables the direct use of culture samples.
Conclusions The PathCrisp assay is precise, specific and rapid, providing results in approximately 2 hours, and operates at a constant temperature, reducing the need for complex equipment handling. In the near future, we hope that this assay can be further optimized and designed as a point-of-care test kit, facilitating its use in various healthcare settings and aiding clinicians in the choice of antibiotics for therapy.
Plain language summary Resistance to Carbapenem, a last-line antibiotic for treatment, is a global threat. Timely diagnosis is critical for a clinician to decide upon the treatment. However, present available methods to detect resistance are either expensive or have longer turnaround time. Here, in this study, we aim to tackle both limitations by developing a rapid, instrument-light, point-of-care assay called PathCrisp. Our PathCrisp assay is a combination of isothermal amplification (a single temperature) and the CRISPR/Cas system used for diagnosis. This provides results within 2 hours and operates at a constant temperature. Our study validated the assay using Carbapenem-resistant Enterobacteriaceae clinical samples to detect the NDM gene, compared to the PCR and sequencing technique previously used. Furthermore, the PathCrisp assay can detect as few as 700 copies of target DNA when tested upon serial dilution, works on crude samples (does not require pure isolated DNA), and can detect NDM-positive samples directly from the culture.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge Rockefeller Foundation Grant Number 2021 HTH 018 and financial aid by Axis Bank for funding the multi-centre AMR mapping and genomic analysis study at Ashoka University. Technical teams from Max Healthcare and Sahyadri Hospital for maintenance of pathogen culture stocks and DNA extractions. Yuvraj J. and Vasundhara K. for building the genomic assemblies. UGC-SAP-DRS-III, DST-FIST and DBT-BIF, Govt. of India for the infrastructural support to the Department of Biosciences, SSSIHL, Prasanthi Nilayam and ICMR-SRF from Govt. of India. Dr. BEP received extramural Research support from ICMR, Govt. of India. Abbireddy Sairam and Harinath Bapat for their support with clinical sample extraction used for assay validation.CRISPRBITS Team self-funded this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee approval was obtained from Sri Sathya Sai Institute of Higher Learning (SSSIHL/IEC/PSN/BS/2014/03) and Sri Venkateswara Institute of Medical Sciences Tirupati (1121 dated 20.03.2021) in accordance with the ethical standards of the Declaration of Helsinki. Further, the Institutional Biosafety Committee of C-CAMP approved the study (BT/IBKP/392/2020) and also from the MedStar Speciality Hospital Ethics Committee (Dated 07022024). Institutional ethics committee approval for the multi-centre study was obtained at Ashoka University. Additionally, both clinical partners viz. Max Healthcare and Sahyadri Hospital obtained ethical clearances from their respective ethics committees.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
